ENT Updates

Clinical Research

Metformin And Dichloroacetate Combination Exert A Synergistic Effect On Cell Viability Of Oral Squamous Cell Carcinoma

Downloads

https://doi.org/10.32448/entupdates.569464
Faruk Calim, O., Selim Yıldırım, Y., Gedik, Özge, Çakır, E., & Özturan, O. (2019). Metformin And Dichloroacetate Combination Exert A Synergistic Effect On Cell Viability Of Oral Squamous Cell Carcinoma. ENT Updates, 9(2). https://doi.org/10.32448/entupdates.569464
Volume 9 Issue 2 (2019)
Copyright (c) 2019 Omer Faruk Calim, Yavuz Selim Yıldırım, Özge Gedik, Erkan Çakır, Orhan Özturan
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors

  • Omer Faruk Calim
    Bezmialem Vakif University, Medical faculty, Department of Otolaryngology Head and Neck Surgery, Istanbul
  • Yavuz Selim Yıldırım Dogus University, Medical Faculty, ENT Department, Istanbul
  • Özge Gedik Bezmialem Vakif University, Health Science Faculty, Department of Audiology, Istanbul
  • Erkan Çakır Bezmialem Vakif University, Medical Faculty, Department of Pediatrics, Istanbul
  • Orhan Özturan Bezmialem Vakif University, Medical faculty, Department of Otolaryngology Head and Neck Surgery, Istanbul

Objective: To assess the effects of Metformin, Dichloroacetate (DCA) and their combination on cell viability in oral squamous cell carcinoma, UPCI-SCC-131 cell line.

Methods: UPCI-SCC-131 cells were plated in 96 E-plate (1x104 cells/well) and were treated with Metformin (1-16mM) and/or DCA (15-120mM) for 24-48-72h. xCELLigence SP system was used to monitor real time cell viability. In addition, drug combination index was analyzed with CompuSyn software according to Chou-Talalay method.

Results: Half-maximal inhibitory concentrations (IC50) of Metformin and DCA were found to be 3mM and 23mM, respectively, for 72 hours. CI values (0.76-0.80) in all combination groups below 1 indicated that Metformin/DCA combination had a moderate synergistic effect on cell viability in UPCI-SCC-131 cells.

Discussion: Metformin/DCA combination synergistically decreased the cell viability of UPCI-SCC-131 cells. Therefore, a combined application of Metformin and DCA may be considered as a candidate therapy for the “drug repositioning” of the treatment of oral cavity cancer.

Keywords:

Metformin Dichloroacetate drug combinations oral cavity cancer